NVCR NovoCure Ltd

Price (delayed)

$192.45

Market cap

$19.9B

P/E Ratio

1,603.75

Dividend/share

N/A

EPS

$0.12

Enterprise value

$20.15B

Sector: Healthcare
Industry: Medical Instruments & Supplies

Highlights

The company's quick ratio has surged by 71% YoY and by 4.4% QoQ
The gross profit has increased by 46% YoY and by 8% QoQ
The equity has surged by 54% year-on-year but it has declined by 22% since the previous quarter
The net income has contracted by 41% from the previous quarter but it has grown by 32% YoY
NVCR's P/E is 115% above its last 4 quarters average of 744.9
NovoCure's debt has increased by 29% from the previous quarter

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
103.41M
Market cap
$19.9B
Enterprise value
$20.15B
Valuations
Price to earnings (P/E)
1,603.75
Price to book (P/B)
52.96
Price to sales (P/S)
37.46
EV/EBIT
597.98
EV/EBITDA
465.04
EV/Sales
38.22
Earnings
Revenue
$527.23M
EBIT
$33.69M
EBITDA
$43.33M
Free cash flow
$99.13M
Per share
EPS
$0.12
Free cash flow per share
$0.97
Book value per share
$3.63
Revenue per share
$5.14
TBVPS
$10.4
Balance sheet
Total assets
$1.07B
Total liabilities
$695.5M
Debt
$572.29M
Equity
$372.13M
Working capital
$904.75M
Liquidity
Debt to equity
1.54
Current ratio
9.19
Quick ratio
8.94
Net debt/EBITDA
5.69
Margins
EBITDA margin
8.2%
Gross margin
79.4%
Net margin
2.2%
Operating margin
6.4%
Efficiency
Return on assets
1.5%
Return on equity
3.3%
Return on invested capital
4.7%
Return on capital employed
3.5%
Return on sales
6.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-0.62%
1 week
-5.71%
1 month
46.13%
1 year
201.46%
YTD
11.22%
QTD
45.6%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$527.23M
Gross profit
$418.84M
Operating income
$33.69M
Net income
$11.73M
Gross margin
79.4%
Net margin
2.2%
The gross profit has increased by 46% YoY and by 8% QoQ
NovoCure's net margin has decreased by 45% from the previous quarter and by 4.3% YoY
The net income has contracted by 41% from the previous quarter but it has grown by 32% YoY
The company's revenue rose by 39% YoY and by 7% QoQ

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
1,603.75
P/B
52.96
P/S
37.46
EV/EBIT
597.98
EV/EBITDA
465.04
EV/Sales
38.22
NVCR's P/E is 115% above its last 4 quarters average of 744.9
NVCR's EPS is down by 40% since the previous quarter but it is up by 20% year-on-year
The price to book (P/B) is 116% higher than the 5-year quarterly average of 24.5 and 60% higher than the last 4 quarters average of 33.1
The equity has surged by 54% year-on-year but it has declined by 22% since the previous quarter
NVCR's price to sales (P/S) is 122% higher than its 5-year quarterly average of 16.9 and 49% higher than its last 4 quarters average of 25.2
The company's revenue rose by 39% YoY and by 7% QoQ

Efficiency

How efficient is NovoCure business performance
The company's return on assets has shrunk by 53% QoQ and by 21% YoY
NovoCure's return on equity has decreased by 46% QoQ and by 25% YoY
NovoCure's ROIC has decreased by 20% from the previous quarter
NVCR's return on sales is up by 4.9% since the previous quarter

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 54% more than its total liabilities
NovoCure's total liabilities has surged by 167% YoY and by 21% QoQ
NovoCure's total assets has soared by 112% YoY
NovoCure's debt is 54% more than its equity
NVCR's debt to equity has soared by 130% YoY and by 66% QoQ
The equity has surged by 54% year-on-year but it has declined by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.